Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 11/20 | 0.78 |
| ▸ | DRD2 | P14416 | 1/20 | 0.60 |
| ▸ | DRD1 | P21728 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | DRD3 | P35462 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10021774 | 0.89 | HTR1A (0.75) | HTR1A | |
| SCHEMBL10021746 | 0.88 | HTR1A (0.62) | HTR1ADRD2DRD1HTR2ADRD3 | |
| SCHEMBL10052723 | 0.88 | HTR1A (1.00) | HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL351933 | 0.86 | HTR1A (0.81) | HTR1ADRD2HTR2ADRD3SLC6A2 | |
| SCHEMBL10021775 | 0.83 | HTR1A (0.67) | HTR1ASLC6A4 | |
| SCHEMBL10021795 | 0.81 | HTR1A (0.68) | HTR1A | |
| SCHEMBL10021790 | 0.80 | HTR1A (0.88) | HTR1A | |
| SCHEMBL10021771 | 0.79 | HTR1A (0.62) | HTR1A | |
| SCHEMBL10021767 | 0.78 | HTR1A (0.67) | HTR1ASLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL10021759 | 0.77 | HTR1A (0.63) | HTR1ADRD2DRD1HTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120016124-A1 | SEROTONIN REUPTAKE INHIBITORS | BAYLOR UNIVERSITY (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120016124-A1 | SEROTONIN REUPTAKE INHIBITORS | BAYLOR UNIVERSITY (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016124-A1 | SEROTONIN REUPTAKE INHIBITORS | HTR2A, HTR2C, HTR1A | HTR1A 3/4885DRD2 54/4885DRD1 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.